Does Insurance Cover GLP-1s? What Actually Gets Reimbursed, and What Doesn't

"Does insurance cover this?" sounds like one question. It is actually three, and insurers answer each one differently: what condition the prescription is written for, what specific plan you're on, and — the question almost no other coverage guide connects to the products this site actually compares — whether the drug you're buying has a National Drug Code a pharmacy claim can even be built around. That third question is the one that determines whether compounded tirzepatide and semaglutide, the category this site exists to compare, are a coverage conversation at all.

Medicare: excluded by statute, then patched by a two-year pilot

Start with the rule that held for two decades before this year. Since the Medicare Part D prescription-drug benefit began, federal law has barred Part D from covering any medication "when used specifically for weight loss" — obesity itself has never been a covered indication, full stop³. People on Medicare have only ever been able to get a GLP-1 covered through Part D by having it prescribed for a different, medically accepted FDA-approved use: type 2 diabetes, cardiovascular-risk reduction, or obstructive sleep apnea. Prescribed for weight loss on its own, the same drug was excluded by statute, not by an insurer's discretionary decision³.

That changed, temporarily, on July 1, 2026. CMS launched the Medicare GLP-1 Bridge, a short-term demonstration program — not a change to the underlying law — that runs through December 31, 2027¹. Under the Bridge, eligible Part D beneficiaries can access select GLP-1s prescribed specifically for obesity at a flat $50 monthly copay, with a prescriber attesting the patient falls into one of several BMI- and comorbidity-based eligibility categories CMS has defined³. Structurally, the Bridge sits outside the normal Part D benefit: CMS uses a single central processor to handle prior authorization, claims adjudication, and payment to pharmacies, and Part D plan sponsors don't carry financial risk for it and don't have to opt in². As of this writing, the covered drugs are limited to the FDA-approved GLP-1s cleared specifically for weight reduction — both formulations of Foundayo and Wegovy, plus the KwikPen formulation of Zepbound³ — which is worth noting mainly for what it excludes: nothing compounded qualifies, because the Bridge, like every mechanism described in this article, only ever pays a pharmacy against a specific FDA-approved, NDC-coded product.

It's also worth being precise about what the Bridge is not: a beneficiary already getting a GLP-1 covered through Part D for diabetes, cardiovascular risk, or sleep apnea keeps using that normal Part D pathway, not the Bridge, and none of this changes anything about Medicaid, where GLP-1 coverage for obesity remains a state-by-state option rather than a federal requirement³. And because it is a demonstration with a hard end date, what happens to a beneficiary's coverage on January 1, 2028 is, per KFF's own read of the program, genuinely unresolved³.

Commercial and employer insurance: real coverage, unevenly distributed

Off Medicare, coverage for the branded, FDA-approved products depends heavily on employer size and appetite for the cost. The Peterson-KFF Health System Tracker's 2025 employer research — built on the KFF Employer Health Benefits Survey plus follow-up interviews with benefits administrators — found that 19% of firms with 200 or more workers covered a GLP-1 for weight loss in their largest health plan in 2025, rising sharply with company size: 43% of firms with 5,000 or more workers did, up from 28% the year before⁴. That growth came with friction. Thirty-four percent of firms that do cover these drugs for weight loss now require enrollees to complete a lifestyle, dietitian, or case-management program first — up from just 10% the prior year — and in interviews, several benefits administrators described utilization running well above what they'd budgeted for, with 44% of firms in the 1,000-4,999 range and 59% of firms above 5,000 workers reporting use "higher than expected," and a comparable share reporting a significant hit to overall prescription-drug spending⁴. Some employers told KFF's researchers they had responded by adding a BMI floor, tightening prior authorization, or dropping weight-loss coverage entirely while keeping it for a documented diabetes diagnosis⁴.

None of that is a guarantee for any individual reader — "43% of large employers" is not "your plan," and the honest answer to "will my job's insurance cover this" is to actually check your formulary, because the variation across plans in that KFF sample is the whole finding, not a footnote to it.

Why compounded tirzepatide and semaglutide are structurally cash-pay

This is the part that separates a generic "does insurance cover GLP-1s" explainer from what actually matters to a reader comparing the providers on this site, because none of the above — Medicare's Bridge, an employer's BMI threshold, a plan's step-therapy rule — is a mechanism that can reach a compounded product in the first place. Here's the reasoning, built on how a pharmacy claim actually gets adjudicated: a standard insurance claim identifies the drug being dispensed by its National Drug Code, a number assigned to a specific, FDA-approved, commercially manufactured product. A pharmacy benefit manager's system checks that NDC against the plan's formulary to decide what it pays. A compounded preparation — mixed to an individual prescription rather than manufactured as a finished commercial product — generally isn't assigned an NDC the same way, and a CVS Caremark member FAQ describing exactly this process states it plainly from the payer's side: to even check whether a compound is covered, a member has to pull "a full list of ingredient names and NDC numbers from the pharmacy" so each individual ingredient can be verified separately against the formulary, and "ingredients not approved by the FDA are typically excluded from coverage unless pre-approved for medical necessity"⁵. The same document states outright that "most compounding pharmacies do not bill insurance" at all, leaving an out-of-pocket paper claim, with no guaranteed outcome, as the only path to any reimbursement⁵. It also lists one specific exclusion category that lands squarely on this site's product category: a compound is generally not covered when it's "made from bulk ingredients when an FDA approved drug is available"⁵ — precisely the situation compounded tirzepatide and semaglutide have been in since the FDA closed the shortage-based compounding exemption in early 2025, as our earlier look at that timeline covers in detail.

To be clear about what is and isn't directly sourced here: no single document states "compounded GLP-1s are never covered by insurance" in those words, and this article isn't claiming one does. What's verifiable is the mechanism — NDC-based claims adjudication, per-ingredient formulary checks, and an explicit "bulk ingredients when an FDA-approved drug is available" exclusion — and that mechanism, read plainly, is why compounded tirzepatide and semaglutide sit almost entirely outside the coverage conversation this article otherwise describes. It's a structural gap, not a temporary oversight insurers are expected to close.

That's also the single biggest reason price transparency matters more for this site's readers than for almost anyone else shopping in healthcare: when a purchase is cash-pay by the pharmacy math itself, not by choice, what a provider actually charges — and what pharmacy is actually filling it — is the whole decision, not one input among several an insurer is also weighing in the background.

What manufacturer savings cards do (and don't) help with

The branded products have a separate, genuinely useful assistance layer that compounded product structurally cannot: manufacturer copay cards. Eli Lilly's Zepbound Savings Card lets a commercially insured patient with plan coverage for the drug pay as little as $25 for a 1-, 2-, or 3-month fill, capped at $100/$200/$300 in monthly savings and $1,300 per calendar year across up to 13 fills, through the card's current 12/31/2026 expiration⁶. Lilly's Mounjaro Savings Card works on the same structure — as little as $25 per month with commercial coverage, capped at $150/$300/$450 across a 1-, 2-, or 3-month fill and $1,950 per year — and both cards' own terms explicitly exclude anyone on a government health program; the eligibility gate is "commercially insured with coverage," full stop⁶⁷. Novo Nordisk's NovoCare savings offers for Wegovy and Ozempic follow the identical pattern: enrollment asks directly whether the applicant is covered by a government or federally funded prescription benefit, the standard screen manufacturer copay-assistance programs use to keep the discount off Medicare, Medicaid, and similar programs⁸⁹. None of these cards are insurance, none of them work without an underlying commercial plan that already covers the drug, and none of them have any mechanism that could extend to a compounded version of the same molecule, for the same NDC-based reason described above.

What this means if you're comparing providers

Put the pieces together and the practical takeaway for this site's readers is narrower than "insurance sometimes covers GLP-1s": if you're in the branded-drug lane and your plan actually covers Zepbound, Wegovy, Mounjaro, or the newly-eligible-for-Medicare products, coverage plus a manufacturer card can bring the out-of-pocket cost down substantially, and that's worth checking before assuming a cash-pay compounded route is automatically cheaper. If you're comparing the compounded providers this site ranks, though, coverage isn't a variable you're weighing at all — every one of them is a cash transaction regardless of what insurance you carry, which is exactly why the disclosure standard our tirzepatide board grades providers against focuses on what a company actually tells you about pharmacy sourcing and pricing rather than on a coverage question that, for this product category, was never really live. The same logic applies even more cleanly to the sermorelin and GH-secretagogue providers ranked separately on this site — that category has no FDA-approved commercial product for insurance to attach a claim to in the first place, so it has been a cash, self-pay category from day one, not one that recently became one.